Neil Bander
Neil Bander
Professor of Urologic Oncology, Weill-Cornell Medicine
Verified email at
Cited by
Cited by
Renal-cell carcinoma
RJ Motzer, NH Bander, DM Nanus
New England Journal of Medicine 335 (12), 865-875, 1996
Mutations of the VHL tumour suppressor gene in renal carcinoma
JR Gnarra, K Tory, Y Weng, L Schmidt, MH Wei, H Li, F Latif, S Liu, ...
Nature genetics 7 (1), 85-90, 1994
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile
J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ...
Science translational medicine 4 (128), 128ra39-128ra39, 2012
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
SS Chang, VE Reuter, WDW Heston, NH Bander, LS Grauer, PB Gaudin
Cancer research 59 (13), 3192-3198, 1999
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
CN Sternberg, A Yagoda, HI Scher, RC Watson, N Geller, HW Herr, ...
Cancer 64 (12), 2448-2458, 1989
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
H Liu, P Moy, S Kim, Y Xia, A Rajasekaran, V Navarro, B Knudsen, ...
Cancer research 57 (17), 3629-3634, 1997
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
NH Bander, MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, ...
Journal of Clinical Oncology 23 (21), 4591-4601, 2005
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium
CN Sternberg, A Yagoda, HI Scher, RC Watson, HW Herr, MJ Morse, ...
The Journal of urology 139 (3), 461-469, 1988
Tumor therapy with targeted atomic nanogenerators
MR McDevitt, D Ma, LT Lai, J Simon, P Borchardt, RK Frank, K Wu, ...
Science 294 (5546), 1537-1540, 2001
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
D Chakravarty, A Sboner, SS Nair, E Giannopoulou, R Li, S Hennig, ...
Nature communications 5 (1), 5383, 2014
Constitutive and antibody-induced internalization of prostate-specific membrane antigen
H Liu, AK Rajasekaran, P Moy, Y Xia, S Kim, V Navarro, R Rahmati, ...
Cancer research 58 (18), 4055-4060, 1998
Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy.
M Mangin, AC Webb, BE Dreyer, JT Posillico, K Ikeda, EC Weir, ...
Proceedings of the National Academy of Sciences 85 (2), 597-601, 1988
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate CancerMT-dependent AR transport underlines Taxane …
MS Darshan, MS Loftus, M Thadani-Mulero, BP Levy, D Escuin, XK Zhou, ...
Cancer research 71 (18), 6019-6029, 2011
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo
JP Holland, V Divilov, NH Bander, PM Smith-Jones, SM Larson, JS Lewis
Journal of Nuclear Medicine 51 (8), 1293-1300, 2010
Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer177Lu-J591 in …
ST Tagawa, MI Milowsky, M Morris, S Vallabhajosula, P Christos, ...
Clinical cancer research 19 (18), 5182-5191, 2013
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody
JP Gleghorn, ED Pratt, D Denning, H Liu, NH Bander, ST Tagawa, ...
Lab on a Chip 10 (1), 27-29, 2010
Phase I trial of yttrium-90—labeled anti—prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, SJ Goldsmith, ...
Journal of clinical oncology 22 (13), 2522-2531, 2004
Superparamagnetic iron oxide nanoparticle–aptamer bioconjugates for combined prostate cancer imaging and therapy
AZ Wang, V Bagalkot, CC Vasilliou, F Gu, F Alexis, L Zhang, M Shaikh, ...
ChemMedChem: Chemistry Enabling Drug Discovery 3 (9), 1311-1315, 2008
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific …
MC Gong, JB Latouche, A Krause, WDW Heston, NH Bander, M Sadelain
Neoplasia 1 (2), 123-127, 1999
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
MJ Evans, PM Smith-Jones, J Wongvipat, V Navarro, S Kim, NH Bander, ...
Proceedings of the National Academy of Sciences 108 (23), 9578-9582, 2011
The system can't perform the operation now. Try again later.
Articles 1–20